Study Details
Testing the Drug Cabozantinib in Pediatric Cancers
(IRB#: IRB_00165978)
Cabozantinib is an approved drug shown to reduce tumor growth. This study will test the drug to treat types of pediatric cancers. The study wants to see if the drug will help people with the pediatric cancers and is safe. People in the study will keep a medical diary and take Cabozantinib as a swallowed tablet to see how the tumor responds. If the tumor becomes smaller or remains the same size and/or if no tumor forms participants may continue taking the study drug for up to 52 weeks. Study participation lasts about 64 weeks. Medical tests will be done to track the health of participants.
- All genders
- All Ages
- Volunteers with special conditions
- In Person
- Unpaid
Who can participate?
Gender: All genders
Age: All Ages
Volunteers: Volunteers with special conditions
Location: In Person
Inclusion Criteria
- Ages less than 7 years to 18 years and older
- Diagnosed pediatric cancer
- Must have recovered from acute toxic effects of prior therapy with specific criteria
- Bone marrow function with specific criteria
- Attend in person visit at the study clinic
Exclusion Criteria
- Previously treated with Cabozantinib
- Pregnant or breastfeeding
- Require corticosteroids and have not been on a stable or decreasing dose
- Must continue to receive other anti-cancer treatments during study participation
- Current uncontrolled infection
Will I be paid for my time?
No
IRB#: IRB_00165978
PI: Matthew Dietz
Department: PEDIATRIC HEMATOLOGY/ONCOLOGY
Approval Date: 2023-11-16 07:00:00
Study Categories: Cancer Studies
Specialties: Pediatric Hematology & Oncology
I am Interested